Ritholtz Wealth Management Takes Position in Oramed Pharmaceuticals Inc. $ORMP

Posted by Geri Gentry on Jul 1st, 2026

Ritholtz Wealth Management acquired a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 155,479 shares of the biotechnology company’s stock, valued at approximately $529,000.

Several other hedge funds have also recently modified their holdings of the stock. SB Capital Management Inc bought a new stake in Oramed Pharmaceuticals in the 4th quarter valued at $5,415,000. HRT Financial LP bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter valued at about $131,000. Jane Street Group LLC grew its position in shares of Oramed Pharmaceuticals by 31.2% during the fourth quarter. Jane Street Group LLC now owns 78,259 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 18,600 shares in the last quarter. Bank of America Corp DE grew its position in shares of Oramed Pharmaceuticals by 4.4% during the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth about $738,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.

View Our Latest Stock Analysis on Oramed Pharmaceuticals

Oramed Pharmaceuticals Stock Up 3.7%

Oramed Pharmaceuticals stock opened at $4.81 on Wednesday. Oramed Pharmaceuticals Inc. has a 52-week low of $1.98 and a 52-week high of $5.19. The firm’s fifty day moving average is $4.07 and its 200 day moving average is $3.60. The company has a market cap of $196.87 million, a price-to-earnings ratio of 1.86 and a beta of 1.26.

Oramed Pharmaceuticals Profile

(Free Report)

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.